[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2388317T3 - Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom - Google Patents

Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom

Info

Publication number
DK2388317T3
DK2388317T3 DK10729101.5T DK10729101T DK2388317T3 DK 2388317 T3 DK2388317 T3 DK 2388317T3 DK 10729101 T DK10729101 T DK 10729101T DK 2388317 T3 DK2388317 T3 DK 2388317T3
Authority
DK
Denmark
Prior art keywords
disease
prevention
treatment
gene encoding
human glucokinase
Prior art date
Application number
DK10729101.5T
Other languages
English (en)
Inventor
Haidong Huang
Original Assignee
Yiyuan (Shenzhen) Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yiyuan (Shenzhen) Biotech Ltd filed Critical Yiyuan (Shenzhen) Biotech Ltd
Application granted granted Critical
Publication of DK2388317T3 publication Critical patent/DK2388317T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002Glucokinase (2.7.1.2)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0362Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10729101.5T 2009-01-07 2010-01-06 Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom DK2388317T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910000087 2009-01-07
PCT/CN2010/070038 WO2010078842A1 (zh) 2009-01-07 2010-01-06 人葡萄糖激酶突变体编码基因、其编码的酶、重组载体及宿主、其药物组合物、应用以及预防和治疗疾病的方法

Publications (1)

Publication Number Publication Date
DK2388317T3 true DK2388317T3 (da) 2017-11-27

Family

ID=42316263

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10729101.5T DK2388317T3 (da) 2009-01-07 2010-01-06 Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom

Country Status (21)

Country Link
US (1) US9029142B2 (da)
EP (1) EP2388317B1 (da)
JP (1) JP5721637B2 (da)
KR (1) KR101300540B1 (da)
CN (1) CN102272296B (da)
AP (1) AP3277A (da)
AU (1) AU2010204379B2 (da)
BR (1) BRPI1006104B8 (da)
CA (1) CA2749180C (da)
DK (1) DK2388317T3 (da)
EA (1) EA024878B1 (da)
ES (1) ES2649021T3 (da)
HU (1) HUE035110T2 (da)
IL (1) IL213750A (da)
MA (1) MA33034B1 (da)
MX (1) MX2011007263A (da)
NZ (1) NZ593893A (da)
PT (1) PT2388317T (da)
SG (1) SG172851A1 (da)
WO (1) WO2010078842A1 (da)
ZA (1) ZA201105209B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2748121C (en) 2008-12-29 2017-12-12 Tel Hashomer Medical Research, Infrastructure And Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
DK2388317T3 (da) 2009-01-07 2017-11-27 Yiyuan (Shenzhen) Biotech Ltd Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom
WO2013117776A1 (es) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
CA2927335C (en) 2014-10-27 2023-05-02 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
CN110564777B (zh) * 2019-09-23 2021-09-10 北京希诺谷生物科技有限公司 糖尿病疾病模型犬的建立方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511353A (ja) * 1997-07-24 2001-08-14 バレンティス・インコーポレーテッド Ghrhの発現システムおよび使用法
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2170720B1 (es) * 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US20070219346A1 (en) * 2002-04-22 2007-09-20 Mcgill University Glucose sensor and uses thereof
WO2005052132A2 (en) * 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0423173D0 (en) * 2004-10-19 2004-11-24 Univ Newcastle Treatment of diabetes
EP1890708A4 (en) * 2005-06-01 2009-07-15 Biotec Inst For Internat GLUCOSE INDUCIBLE INSULIN EXPRESSION AND METHODS OF TREATING DIABETES
WO2009021276A1 (en) * 2007-08-10 2009-02-19 University Of Technology, Sydney Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof
DK2388317T3 (da) 2009-01-07 2017-11-27 Yiyuan (Shenzhen) Biotech Ltd Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom

Also Published As

Publication number Publication date
HUE035110T2 (en) 2018-05-02
MX2011007263A (es) 2011-10-06
AP2011005814A0 (en) 2011-08-31
JP5721637B2 (ja) 2015-05-20
EA024878B1 (ru) 2016-10-31
KR101300540B1 (ko) 2013-09-02
EP2388317A4 (en) 2012-11-28
AU2010204379B2 (en) 2014-02-13
CN102272296A (zh) 2011-12-07
US20110286984A1 (en) 2011-11-24
CN102272296B (zh) 2012-10-24
ES2649021T3 (es) 2018-01-09
CA2749180A1 (en) 2010-07-15
JP2012514463A (ja) 2012-06-28
AU2010204379A1 (en) 2011-07-28
EP2388317B1 (en) 2017-08-30
WO2010078842A1 (zh) 2010-07-15
EP2388317A1 (en) 2011-11-23
BRPI1006104B1 (pt) 2021-04-20
CA2749180C (en) 2017-03-21
BRPI1006104B8 (pt) 2021-05-25
EA201170917A1 (ru) 2011-12-30
NZ593893A (en) 2013-02-22
KR20110099057A (ko) 2011-09-05
ZA201105209B (en) 2012-09-26
SG172851A1 (en) 2011-08-29
IL213750A0 (en) 2011-07-31
US9029142B2 (en) 2015-05-12
PT2388317T (pt) 2017-11-27
AP3277A (en) 2015-05-31
IL213750A (en) 2015-11-30
MA33034B1 (fr) 2012-02-01
BRPI1006104A2 (pt) 2016-02-16

Similar Documents

Publication Publication Date Title
DK2388317T3 (da) Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
DK2808024T3 (da) Bifidobakterier til behandling af kongestiv hjerteinsufficiens
BR112012008058A2 (pt) implantes e modelos ortopédicos específicos para o paciente.
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
EP2097012A4 (en) DEVICES AND METHOD FOR TREATING HEART FAILURE
EP2349140A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA
EP2485638A4 (en) DEVICES, MEDICAL PRESSURE DETECTION SYSTEMS AND METHODS, AND METHODS OF MANUFACTURING MEDICAL DEVICES
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2417257T3 (da) Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
WO2010083347A3 (en) Peptidomimetic macrocycles
EP2220046A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP2220076A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP2220084A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2486334T3 (da) Fremgangsmåder og anordninger til fortrængning af kropskonvektion og tilvejebringelse af en kontrolleret, personlig vejrtrækningszone
EP2401264A4 (en) PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
DK2384327T3 (da) Forbindelse med kondenseret ring og anvendelse deraf.
DK2750551T3 (da) Ortopædisk stol til behandling og forebyggelse af rygmarvslidelser
EP2337535A4 (en) SYSTEMS, DEVICES AND METHODS FOR THE TREATMENT OF ACOUPHEN
BR112013015771A2 (pt) derivados de ciclosporina para o tratamento e a prevenção de uma infecção viral
DK3216457T3 (da) Forbindelser og fremgangsmåder til forebyggelsen eller behandlingen af restenose